B. Riley Issues Positive Forecast for Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price

Centessa Pharmaceuticals (NASDAQ:CNTA) had its target price hoisted by B. Riley from $33.00 to $42.00 in a research report report published on Monday,Benzinga reports. B. Riley currently has a buy rating on the stock.

Several other research firms have also commented on CNTA. Oppenheimer assumed coverage on shares of Centessa Pharmaceuticals in a research note on Friday, August 29th. They issued an “outperform” rating and a $40.00 price objective for the company. Guggenheim increased their target price on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Truist Financial set a $30.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company lifted their target price on Centessa Pharmaceuticals from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $35.50.

Centessa Pharmaceuticals Trading Down 1.9%

CNTA opened at $28.47 on Monday. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $29.99. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The business has a fifty day simple moving average of $24.62 and a 200-day simple moving average of $18.77. The firm has a market cap of $3.83 billion, a P/E ratio of -15.56 and a beta of 1.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). On average, equities analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Mario Alberto Accardi sold 8,000 shares of the firm’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $25.00, for a total transaction of $200,000.00. Following the sale, the insider owned 194,394 shares of the company’s stock, valued at approximately $4,859,850. This trade represents a 3.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Tia L. Bush sold 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total value of $1,040,000.00. Following the sale, the chief technology officer owned 121,503 shares of the company’s stock, valued at approximately $3,159,078. The trade was a 24.77% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 179,964 shares of company stock worth $4,106,481 over the last ninety days. Corporate insiders own 7.09% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $218,000. Cutter Capital Management LP raised its position in Centessa Pharmaceuticals by 184.3% in the first quarter. Cutter Capital Management LP now owns 418,127 shares of the company’s stock worth $6,013,000 after acquiring an additional 271,051 shares in the last quarter. American Century Companies Inc. lifted its holdings in Centessa Pharmaceuticals by 1.2% in the first quarter. American Century Companies Inc. now owns 1,092,754 shares of the company’s stock valued at $15,714,000 after acquiring an additional 13,046 shares during the period. Wellington Management Group LLP boosted its position in shares of Centessa Pharmaceuticals by 20.6% during the 1st quarter. Wellington Management Group LLP now owns 138,767 shares of the company’s stock worth $1,995,000 after purchasing an additional 23,660 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth $3,273,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.